Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lutetium Lu 177 LNC1004

A radioconjugate consisting of an Evans blue (EB) modified fibroblast activation protein inhibitor (FAPi), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecane tetraacetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity. Upon administration of lutetium Lu 177 LNC1004, the FAPi moiety targets and binds to FAP-expressing cancer-associated fibroblasts (CAFs). Upon binding and internalization, the radioconjugate specifically delivers a cytotoxic dose of beta radiation to FAP-expressing CAFs. FAP, a cell surface protein, is overexpressed on CAFs in the tumor microenvironment (TME).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:177Lu-LNC1004
lutetium Lu 177-LNC1004
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search